MetaCap

Gyre Therapeutics (GYRE) vs Neurogene (NGNE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neurogene (NGNE) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 10.4% versus a loss of 44.2%. Over five years, GYRE leads with a -77.5% price change compared with -78.3% for NGNE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $458.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GYRE-44.24%NGNE+10.42%
+122%+33%-55%
Nov 21, 20251 yearNov 20, 2026
GYRE-78.58%NGNE-79.10%
+59%-20%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GYRE versus NGNE key metrics
MetricGYRENGNE
Share price$4.21$22.15
Market cap$460.79M$458.53M
1-day change-6.86%-3.40%
YTD return-40.37%+7.52%
1-year return-44.24%+10.42%
5-year return-77.55%-78.33%
Forward P/E70.17—
EPS (TTM)$-0.31$-5.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$116.59M$0
Revenue growth (YoY)+10.24%-100.00%
Net income (latest FY)$9.88M$-90.35M
Gross margin95.35%—
Operating margin9.85%—
Net margin8.47%—
52-week high$9.14$43.66
52-week low$3.97$15.93
Distance from 52-week high-53.94%-49.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+343.47%+250.47%
Average volume181.04K307.78K
Shares outstanding109.45M20.70M
Employees625131
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NGNE has outperformed GYRE by 54.7 percentage points over the past year.
  • Gyre Therapeutics grew revenue faster in its latest fiscal year (+10.24% vs -100.00%).

About Gyre Therapeutics

GYRE stock →

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees

About Neurogene

NGNE stock →

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees

GYRE vs NGNE FAQ

Which is bigger, Gyre Therapeutics or Neurogene?

Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $458.53M for Neurogene (NGNE).

Which stock has performed better over the past year, GYRE or NGNE?

NGNE returned +10.42% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.

Are Gyre Therapeutics and Neurogene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons